DVAX Dynavax Total Asset Value of Company

Dynavax Technologies (DVAX) is stabilizing revenues through the synthesis of hepatitis B vaccines and the supply of adjuvants to partners, while simultaneously reducing industrial waste and implementing energy-saving measures. This chart of historical total asset quotes on GURU.Markets shows a value of 1004.63. However, global instability and sanctions are complicating component logistics and disrupting clinical trial timelines across several regions.

DVAX (Dynavax Corp) Company Total Assets history from 07/04/2022 to 02/21/2026

Analytical breakdowns and data insights for company Dynavax (DVAX)

- stock quotes and analyst forecast:

Share Price Dynavax Technologies|DVAX - Price Target Chart

- market capitalization data:

Market Valuation Dynavax Pharma|DVAX - Enterprise Value

- issuer book value statistics:

Accounting Value of a Share Dynavax|DVAX - Book Capitalization|Market Capitalization to Book Value Ratio dynavax.com|DVAX - Aggregate Company Assets

- debt burden and liquidity indicators:

All Debt to Shareholders' Equity Ratio Dynavax Technologies|DVAX - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Dynavax Technologies Corporation|DVAX - Company Aggregate Debts|Debts to Book Capitalization Dynavax Pharma|DVAX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Dynavax|Quick Liquidity dynavax.com

- net income and valuation multiples indicators:

DVAX - Net Profit

Fundamental valuation:Dynavax Technologies

Manufactured products of Dynavax Technologies Corp

This indicator reflects the firm's total resource volume, calculated inversely via daily ROA, where local contraction may signal either a business decline or preparation for a fundamental rebound. By analyzing current balance sheet assets, the investor assesses the capitalization of Dynavax Technologies (DVAX) proprietary adjuvant technology, which creates a competitive moat against medical holdings through vaccination efficiency.

Key competitors

Total Business Assets ARWR|Aggregate Company Assets Mirum|Arbutus Biopharma Corp - Total Asset Value of Company|Company Total Assets IVA|GYRE (Gyre Therapeutics Corp.) - Aggregate Asset Value|Company Total Assets ASMB (Assembly Biosciences)|Company Total Assets Galectin Therapeutics, Inc. GALT|GNFT - Aggregate Company Assets|Aggregate Asset Value DRRX (DURECT Corporation)|aligos.com (ALGS) - Aggregate Company Assets|Cumulative Company Assets BioVie|GLMD (Galmed Pharmaceuticals Ltd) - Company Total Assets|Company Total Assets endrainc.com|Cumulative Company Assets HEPA (Hepion Pharmaceuticals)